ResultsIQ › Latest results › Procter & Gamble Health Limited
Procter & Gamble Health Limited Q2 FY27 results press release summary
NSE: PGHL · BSE: 500126
Results press release of 2 Nov 2026, summarised by AI from the filing.
P&G Health Q2 FY27 sales ₹376 cr, up 18%, and reported PAT ₹112 cr, up 26% versus a year ago.
Key takeaways
- Sales Q2 FY27 sales ₹376 cr, up 18% versus a year ago.
- PAT Reported PAT ₹112 cr, up 26% versus a year ago.
- Momentum Management says the quarter continues the momentum of the previous quarters with double-digit topline and bottom-line growth.
- Growth drivers Brand fundamentals, retail execution, new innovations and go-to-market capabilities drove sales.
- Preventive health Management points to growing consumer focus on preventive health behind demand for its healthcare products.
Procter & Gamble Health Limited Q2 FY27 results
As filed: Revenue ₹382 cr (+18% year on year), EBITDA ₹152 cr (+27% year on year), PAT ₹112 cr (+25% year on year), EBITDA margin 39.8% (+291 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹364 cr (+7% year on year), EBITDA ₹99.6 cr (+11% year on year), PAT ₹96.2 cr (+9% year on year), EBITDA margin 27.4% (+84 bps). Score 40 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin rose 84 bps year on year. Profit fell 27% from last quarter. Share price after the results: −12.4% in 29 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹370 cr (+19% year on year), EBITDA ₹136 cr (+67% year on year), PAT ₹94.6 cr (+55% year on year), EBITDA margin 36.6% (+1,000 bps). Score 81 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 1000 bps year on year. Profit rose ₹33.6 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: +10.3% in 30 days (Nifty 500: +0.9%).
- Q3 FY26: Revenue ₹374 cr (+21% year on year), EBITDA ₹110 cr (−11% year on year), PAT ₹77.6 cr (−15% year on year), EBITDA margin 29.6% (−1,000 bps). Score 44 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 1000 bps year on year. Profit fell 13% from last quarter. Share price after the results: −6.8% in 28 days (Nifty 500: −4.0%).
- Q2 FY26: Revenue ₹325 cr (+4% year on year), EBITDA ₹120 cr (+5% year on year), PAT ₹89.0 cr (+9% year on year), EBITDA margin 36.9% (+50 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 50 bps year on year. Revenue fell 4% from last quarter. Share price after the results: −5.8% in 30 days (Nifty 500: +0.7%).
- Q1 FY26: Revenue ₹339 cr (+19% year on year), EBITDA ₹90.0 cr (+88% year on year), PAT ₹66.0 cr (+288% year on year), EBITDA margin 26.6% (+965 bps). Score 90 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 965 bps year on year. Share price after the results: +8.0% in 28 days (Nifty 500: −2.0%).
- Q4 FY25: Revenue ₹311 cr (+23% year on year), EBITDA ₹81.0 cr (+19% year on year), PAT ₹61.0 cr (+30% year on year), EBITDA margin 26.1% (−94 bps). Score 71 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 94 bps year on year. Profit fell 33% from last quarter. Share price after the results: −0.6% in 30 days (Nifty 500: +1.9%).
- Q3 FY25: Revenue ₹310 cr (0% year on year), EBITDA ₹124 cr (+22% year on year), PAT ₹91.0 cr (+26% year on year), EBITDA margin 40.0% (+710 bps). Score 65 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 710 bps year on year.
Past price moves after results do not indicate future moves. Not a recommendation.
Procter & Gamble Health Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results press release (2 Nov 2026)
- Q1 FY27: Results press release (6 Aug 2026)
- Q4 FY26: Results press release (26 May 2026)
- Q3 FY26: Results press release (6 Feb 2026)
- Q2 FY26: Results press release (5 Nov 2025)
- Q1 FY26: Results press release (1 Aug 2025)
- Q4 FY25: Results press release (29 May 2025)
- Other events: Investor meet (18 Jun 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.